Intec Pharma Ltd (NTEC) Upgraded to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Intec Pharma Ltd (NASDAQ:NTEC) from a hold rating to a buy rating in a research note released on Friday. The firm currently has $5.50 price objective on the stock.

According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “

Separately, Maxim Group restated a buy rating and issued a $9.00 price target on shares of Intec Pharma in a research note on Friday.

Shares of Intec Pharma (NASDAQ:NTEC) traded down 1.96% on Friday, reaching $5.00. 120 shares of the company traded hands. The firm’s 50 day moving average is $4.83 and its 200 day moving average is $5.22. The company’s market capitalization is $57.00 million. Intec Pharma has a one year low of $3.03 and a one year high of $6.36.

COPYRIGHT VIOLATION NOTICE: This story was posted by Mideast Time and is the property of of Mideast Time. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

5 Day Chart for NASDAQ:NTEC

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Intec Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2017 Mideast Time.